<DOC>
	<DOCNO>NCT00505089</DOCNO>
	<brief_summary>This study investigate pharmacokinetic ( PK ) / total IL-1beta pharmacodynamic ( PD ) relationship joint fluid patient rheumatoid arthritis ( RA ) treat different dos ACZ885 evaluate impact subcutaneous ( s.c. ) versus intravenous ( i.v . ) route administration .</brief_summary>
	<brief_title>Efficacy Safety Subcutaneous Versus Intravenous ACZ885 Adult Patients With Established Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Male female patient age 18 75 year ( inclusive ) . Body weight must 50 100 kg ( inclusive ) . Postmenopausal surgically sterile female patient . Women childbearing potential already stable dose methotrexate practice effective contraception least 3 month prior screen , negative pregnancy test screen baseline , willing use 2 form contraception include least 1 barrier method study least 2 month follow completion/discontinuation study . Male patient must willing use effective contraception method study least 2 month follow completion/discontinuation study . Diagnosis Rheumatoid Arthritis , classify ARA ( American Rheumatism Association ) 1987 revise criterion ( Appendix 2 ) . Disease duration least 6 month prior randomization essential . Functional status class I , II III classify accord ACR ( American College Rheumatology ) 1991 revise criterion ( Appendix 3 ) . Active disease screen baseline ( Day 1 predose ) evaluation ( evaluator ) : ≥ 6 tender ≥ 6 swollen joint 28 examine ( include effuse joint ) either ) Westergren erythrocyte sedimentation rate ( ESR ) ≥ 28 mm/hour , b ) Creactive protein ( CRP ) ≥ 1.0 mg/dL . Prior treatment 13 diseasemodifying antirheumatic drug ( DMARDs ) Patients fail least 1 DMARD deem `` refractory therapy '' . Patients current treatment methotrexate ≤ 25 mg/week current dose stable least 3 month . All patient take folic acid 1 mg daily , 5 mg weekly post MTX dose , minimize toxicity , accord local guideline . In addition methotrexate , patient may either stable dose nonsteroidal antiinflammatory drug ( NSAIDs ) and/or stable dose oral corticosteroid ( prednisone equivalent ≤ 10 mg daily ) least 4 week prior randomization . Patients fail DMARDs allow . Negative purify protein derivative ( PPD ) tuberculin skin test reaction ( PPD 5 tuberculin unit accord local standard practice ) . Patients total white cell count platelet count clinically acceptable patient RA ; hemoglobin must ≥ 10 g/dL hematocrit ≥ 30 % screen baseline . Previous treatment antiTNFα anti IL1 therapy ( biological therapy ) , immunosuppressive agent cyclosporine , mycophenolate tacrolimus . The follow washout period require patient eligible participate trial . 1 . 2 month washout prior screen etanercept adalimumab 2 . 3 month washout prior screen infliximab 3 . 3 month washout prior screen rituximab 4 . 1 month washout prior screen cyclosporine , mycophenolate tacrolimus . If patient discontinue DMARDs lack efficacy toxicity , patient least 1 month agent effect agent dissipate accord recognize duration effect ( e.g. , sulfasalazine , hydroxychloroquine ) , standard washout procedure ( cholestyramine leflunomide ) . Importantly , discontinuation undertaken purpose participation study . Patients receive intraarticular systemic corticosteroid injection require treatment acute RA flare ( part regular therapeutic regimen ) within four week prior randomization . Presence history Major chronic inflammatory autoimmune disease like psoriasis , psoriatic arthritis , spondyloarthropathy , inflammatory bowel disease systemic lupus erythematosus . Renal trauma , glomerulonephritis patient one kidney . Patients congestive heart failure ( New York Heart Association class &gt; III ) , QT prolongation syndrome poorly control diabetes mellitus . Patients history QTc prolongation exclude . A positive HIV test result , Hepatitis B surface antigen Hepatitis C test result . Significant illness within 2 week prior dose active systemic infection medical condition may require treatment therapeutic intervention study . Hypersensitivity biological agent , serious allergic reaction , collagen disease , neurological disease ( include demyelinate disease ) . Any joint surgery past 8 week plan surgery within next 5 month . Cancer ( basal cell cancer adequately treat carcinomainsitu cervix ) . Drug alcohol abuse within 12 month prior dose evidence indicate laboratory assay conduct screen baseline evaluation . Underlying metabolic , endocrine , hematologic , pulmonary , cardiac , blood , renal , hepatic , infectious , psychiatric gastrointestinal condition place patient unacceptable risk participation study immunomodulatory therapy . Treatment investigational agent within 12 week prior enrollment longer required local regulation . Pregnant breastfeed woman . Donation loss 400 mL blood within 8 week prior dose Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>pharmacokinetic , pharmacodynamic , subcutaneous , intravenous , ACZ885 , patient , rheumatoid , arthritis .</keyword>
</DOC>